C4 Therapeutics, Inc. announced the appointment of Leonard (Len) Reyno, M.D., as chief medical officer, effective July 10, 2023. Dr. Reyno is a seasoned biotech executive with nearly 30 years of clinical development experience, spanning first-in-human studies to Phase IV clinical trials. At C4T, Dr. Reyno will be responsible for driving C4Ts clinical strategy to advance its promising pipeline of degrader therapies.

Dr. Reyno joins C4T from Pionyr Immunotherapeutics, where he most recently served as president, research &development and chief medical officer and led the company to advancing two novel therapeutics into the clinic. Prior to Pionyr, he was executive vice president and chief medical officer at ORIC Pharmaceuticals, leading their first product candidate into human trials. Before that, he served in various medical leadership roles at Agensys, a subsidiary of Astellas Pharma, over the course of a decade; there, he led clinical-stage development of multiple antibody products to novel targets through clinical proof of concept, including the early clinical development of Padcev for bladder cancer.

Earlier in his career, at Genentech and Aventis, Dr. Reyno led FDA approval teams for Herceptin for HER2+ breast cancer and Taxotere for the adjuvant treatment of breast cancer, respectively. Prior to joining industry, Dr. Reyno was an academic oncologist at Queen Elizabeth II Health Sciences Centre in Nova Scotia, Canada, and previously at McMaster University where he gained extensive experience as a clinician as well as serving as a principal investigator on multiple trials with the National Cancer Institute of Canada. Dr. Reyno earned a B.Sc.

in chemistry at Dalhousie University and an M.D. from McMaster University Medical School.